The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net income (loss) | 3,052 | 1,960 | 1,315 | 1,783 |
| Depreciation expense | 90 | 93 | 97 | 95 |
| Amortization expense | 596 | 598 | 599 | 598 |
| Stock-based compensation expense | 230 | 225 | 209 | 222 |
| Deferred income taxes | 659 | -178 | -199 | -379 |
| Net (gain) loss from equity securities | 482 | 142 | -426 | -126 |
| Acquired in-process research and development expenses | 170 | 62 | 253 | -11 |
| In-process research and development impairments | 0 | 190 | 0 | 0 |
| Other, net | -89 | -33 | -91 | -59 |
| Accounts receivable, net | 333 | 292 | -79 | -72 |
| Inventories | 515 | 175 | 223 | 226 |
| Prepaid expenses and other | 368 | -81 | -12 | 146 |
| Accounts payable | 230 | -162 | -105 | -58 |
| Income tax assets and liabilities, net | -122 | -1,300 | -552 | 536 |
| Accrued and other liabilities | 811 | -166 | -244 | 305 |
| Net cash provided by operating activities | 4,108 | 827 | 1,757 | 2,975 |
| Purchases of marketable debt securities | 270 | 2,287 | 0 | 0 |
| Proceeds from sales of marketable debt securities | 219 | 295 | 0 | 0 |
| Proceeds from maturities of marketable debt securities | 17 | 15 | 0 | 0 |
| Acquisitions, including in-process research and development, net of cash acquired | 167 | 21 | 273 | 75 |
| Purchases of equity securities | 82 | 21 | 16 | 39 |
| Purchases of property, plant and equipment | 147 | 107 | 104 | 147 |
| Other investing activities, net | -4 | -10 | 23 | -35 |
| Net cash used in investing activities | -427 | -2,116 | -415 | -225 |
| Proceeds from debt financing, net of issuance costs | - | - | - | 3,464 |
| Proceeds from issuances of common stock | 97 | 27 | 252 | 173 |
| Repurchases of common stock under repurchase programs | 435 | 527 | 730 | 350 |
| Repayments of debt and other obligations | 9 | 9 | 1,762 | 7 |
| Payments of dividends | 1,005 | 994 | 1,010 | 973 |
| Other financing activities, net | -137 | -64 | -176 | -47 |
| Net cash used in financing activities | -1,489 | -1,567 | -3,426 | 2,260 |
| Effect of exchange rate changes on cash and cash equivalents | -5 | 73 | 19 | -55 |
| Net change in cash and cash equivalents | 2,187 | -2,783 | -2,065 | 4,955 |
| Cash and cash equivalents at beginning of period | 5,144 | 7,926 | 9,991 | 5,037 |
| Cash and cash equivalents at end of period | 7,330 | 5,144 | 7,926 | 9,991 |
GILEAD SCIENCES, INC. (GILD)
GILEAD SCIENCES, INC. (GILD)